Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

Randomized phase II study of CPT‑11 versus PTX versus each combination chemotherapy with S‑1 for advanced gastric cancer that is refractory to S‑1 or S‑1 plus CDDP: OGSG0701

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201

Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108)

切除不能進行・再発大腸癌に対する後方ラインにおける レゴラフェニブ療法とS-1＋ベバシズマブ併用療法の 無作為化比較第Ⅱ相試験（OGSG1301）

Docetaxel plus S‑1 versus cisplatin plus S‑1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS‑3)

Phase II Study of Panitumumab Monotherapy in Chemotherapy- Naive Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer OGSG 1602

A phase II trial of dose‑reduced nab‑paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

Comparison of S‑1–cisplatin every 5 weeks with capecitabine‑cisplatin every 3 weeks for HER2‑negative gastric cancer (recurrent after S‑1 adjuvant therapy or chemotherapy‑naïve advanced): pooled analysis of HERBIS‑2 (OGSG 1103) and HERBIS‑4A (OGSG 1105) trials